INTERVENTIONS FOR VALVULAR DISEASE AND HEART FAILURE

Early commercial experience from transcatheter aortic valve implantation using the Portico™ bioprosthetic valve: 30-day outcomes in the multicentre PORTICO-1 study

EuroIntervention 2018;14:886-893 published online ahead of print August 2018. DOI: 10.4244/EIJ-D-18-00343

Francesco Maisano
Francesco Maisano1*, MD, FESC; Stephen Worthley2, MD; Josep Rodés-Cabau3, MD; Axel Hans-Peter Linke4, MD; Stephan Fichtlscherer5, MD; Ulrich Schäfer6, MD; Raj Makkar7, MD; Gregory Fontana8, MD; Federico M. Asch9, MD; Lars Søndergaard10, MD
1. Clinic for Heart and Vascular Surgery, University Hospital Zurich, Zurich, Switzerland; 2. Royal Adelaide Hospital, Adelaide, Australia; 3. Quebec Heart and Lung Institute, Laval University, Quebec, Canada; 4. Technical University Dresden, Heart Center

Aims: The aim of this study was to investigate the procedural and short-term outcomes of transcatheter aortic valve implantation (TAVI) with the Portico™ self-expanding, resheathable TAVI

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

aortic stenosisclinical trialdegenerative valvetavi
Read next article
Main pulmonary artery perforations after left atrial appendage occluder implantation

Latest news